In DURATION-1, Drucker et al sought to compare a long-acting-release formulation of exenatide (2 mg, injected once weekly) with 10-µg exenatide injected twice per day in 295 patients with type 2 ...
One thing that all sides agree on in the tripartite fight over control of Amylin's board of directors is that the launch of exenatide once weekly, the long-acting version of its diabetes drug Byetta, ...
New Orleans, LA - Once-weekly treatment with the investigational agent exenatide (Byetta, Amylin Pharmaceuticals) resulted in better glycemic control than either daily sitagliptin (Januvia, Merck) or ...
Please provide your email address to receive an email when new articles are posted on . Umpierrez and colleagues conducted a multicenter, prospective, open-label, randomized trial with 150 adults who ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — A once-weekly injection of exenatide may be an important therapeutic option for patients with type 2 ...
Investigational GLP-1 Treatment Improved Glucose Control with Just One Dose per Month SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: ...
LOS ANGELES, CA—The experimental agent exenatide appears cardioprotective in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), ...
A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier 'proof of concept' clinical trial using exenatide showed that improvements persisted 12 months after ...
As an adjunct to primary percutaneous coronary intervention (PCI), the experimental agent exenatide is cardioprotective in patients with ST-segment elevation myocardial infarction (STEMI)—but only in ...
Even with treatment, such as combined metformin and sulfonylurea, glycemic control can be compromised in patients with type 2 diabetes. Furthermore, these drugs are associated with weight gain. There ...
The 121-patient, phase 2 study assessed the efficacy, safety and tolerability of three different doses of exenatide once monthly. It also assessed exenatide once weekly (exenatide extended-release for ...
The 121-patient, phase 2 study assessed the efficacy, safety and tolerability of three different doses of exenatide once monthly. It also assessed exenatide once weekly (exenatide extended-release for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results